HCA HCA Healthcare Inc

HCA Announces Michael W. Michelson Appointed as New Independent Director

HCA Healthcare, Inc. (NYSE: HCA) today announced that its board of directors has appointed Michael W. Michelson as an independent director, effective immediately. With his addition, HCA’s board of directors increased from 11 to 12 members. Mr. Michelson will also serve as a member of the Company’s Audit and Compliance Committee and Finance and Investments Committee.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180117006395/en/

HCA Healthcare Board Member Michael Michelson (Photo: Business Wire)

HCA Healthcare Board Member Michael Michelson (Photo: Business Wire)

Mr. Michelson joined KKR in 1981 and has played a significant role investing in and developing the firm’s portfolio companies. He began his professional career with the law firm of Latham & Watkins in Los Angeles, where he was involved in a broad corporate practice. He earned an A.B. from Harvard College and a J.D. from Harvard Law School. Mr. Michelson also previously served as a director of HCA from 2006 to 2016.

R. Milton Johnson, chairman and chief executive officer of HCA, commented, “We are very excited to have Mike rejoin our board of directors. I am confident that his extensive business experience and financial expertise, including his knowledge of HCA and the healthcare industry, will be a valuable resource to the Company going forward.”

All references to “Company” and “HCA” as used throughout this document refer to HCA Healthcare, Inc. and its affiliates.

EN
17/01/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HCA Healthcare Inc

HCA Healthcare Inc: 2 directors

Two Directors at HCA Healthcare Inc sold/sold after exercising options 12,020 shares at between 505.000USD and 514.582USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by al...

HCA Healthcare, Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Magnificent Seven's Turn to Shine We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass). We will maintain our bullish intermediate-term outlook as long as market dynamics remain healthy and the S&P 500 (SPX) is above 6200 (up from 6028-6059). Additionally, we discussed since our 10/14/25 Compass how our near-term bullish outlook remains intact as long as the SPX holds above 6550-6569, which coincided with the ...

HCA Inc.: Update to credit analysis following upgrade to Baa2

Our credit view of this issuer reflects its significant scale and strong free cash flow, offset by its history of shareholder-friendly policies.

Moody's Ratings assigns Baa2 rating to HCA's proposed senior unsecured...

Moody's Ratings (Moody's) assigned Baa2 ratings to HCA Inc.'s ("HCA") proposed offering of backed senior unsecured notes of up to $3.25 billion with various maturities. HCA intends to use the net proceeds from this offering for general corporate purposes including repayment of outstanding borrowings...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch